Term
supportive care is defined as maximizing?
there is no specific? |
|
Definition
|
|
Term
| the two big targets in supportive care is-2 |
|
Definition
|
|
Term
| chemo drugs affects rapid dividing cells where-3 |
|
Definition
tumor
bone marrow
muscal linig in mouth, GI, etc |
|
|
Term
|
Definition
anemia
neutropenia
mucositis/stomatitis |
|
|
Term
| look at slide 6 and 7 for overview of hematopoesis |
|
Definition
|
|
Term
anemia in men def
in women |
|
Definition
|
|
Term
grade/toxicity of anemia:
hgb>11 |
|
Definition
|
|
Term
grade/toxicity of anemia:
hgb 10ish |
|
Definition
|
|
Term
grade/toxicity of anemia:
hgb 8-10 |
|
Definition
|
|
Term
grade/toxicity of anemia:
6.5-7.9 |
|
Definition
|
|
Term
grade/toxicity of anemia:
hbg <6.5 |
|
Definition
|
|
Term
| what 3 cancers result in the most Hgb loss- |
|
Definition
|
|
Term
|
Definition
chronic
chemo
mineral def
disease related |
|
|
Term
|
Definition
decrease QOL
increase trnasfusion
decrease survival |
|
|
Term
| what chemo predispooses for anemia-2 |
|
Definition
platimun meds
combo therapyies |
|
|
Term
| predisposing factors for anemia besides chemo-4 |
|
Definition
radiation
chronic renal fail
myelodyplastic
comorbidities: ex- cancer |
|
|
Term
| chemo agnets/combos with omst Grade 3-4 anemias-4 |
|
Definition
docetaxel
VIP
cisplatin-etoposide
CHOP |
|
|
Term
| chemo agnets wiht the most Grade1-2 anemias |
|
Definition
paclitexal-dox; paclit-carbo
docetaxel |
|
|
Term
|
Definition
trnasfusion
ESA
non ESAs
supplements |
|
|
Term
| beenfit of trnasfusion for anemia-1 |
|
Definition
| quick enhancement. get 1 dL increase in 1 hr |
|
|
Term
| cons of doing trnasfsuion for anemia-5 |
|
Definition
graft vs host
allergy
infections
replase
worse prognossi |
|
|
Term
| use of _ has decrease the use of trnasfusion in anemic cancer pts |
|
Definition
|
|
Term
| MOa of ESA (erythopoietin) |
|
Definition
| stimulates red bone marrow->more EPO->RBCs |
|
|
Term
|
Definition
epoetin a,b,delta
darpoetin alpha
CERA |
|
|
Term
| longest half life agnet rHuEPO: |
|
Definition
|
|
Term
|
Definition
|
|
Term
erythoptein vs darpoetin:
which has more chains?
more half life? |
|
Definition
|
|
Term
Epoetin alpha dosing and admin
150 U-
40,000
10,000 |
|
Definition
3 times weekly, Iv/SC
q week IV/SQ
3 times weekly IV/SQ |
|
|
Term
| administraitn for darbopetin |
|
Definition
|
|
Term
dosing frq for dabopoetin
500
300q
200
2.5 mcg/kg |
|
Definition
|
|
Term
| the biggest event of using EPOs/ERAs is |
|
Definition
|
|
Term
| overtime which results in higher hgb- trnasfusion or EPO? |
|
Definition
|
|
Term
| safety of ESA/EPOs- increased _ and decreased_ |
|
Definition
thombolytic events
overall survival |
|
|
Term
| HR for mortality greater in ESA or non ESA cancer tx? |
|
Definition
|
|
Term
| * ESA tx in cancer pts decreased survival, if taking chemo it was less pronounced but cant rule it out! |
|
Definition
|
|
Term
| EPO effects tumor bc there are recpt on the tumor surface** (so increase prolif of cance cell, and metastais of tumor) |
|
Definition
|
|
Term
|
Definition
chronic kid disease, CKD from T2DM
temporary in chemo-oinduced for solid canc. stop when chemo ends
HIV induced
undergoing replacment surgery
hep, SLe, chron's |
|
|
Term
|
Definition
|
|
Term
| dont use ESAs in what type of cancers |
|
Definition
| hematological bc these ppl are already rpone to anemia |
|
|
Term
| ESAs shouldnt relaly be used for cnacer induced anemia either* |
|
Definition
|
|
Term
|
Definition
|
|
Term
| give ESA to certain chemo pts when Hgb< _ and goal is hgb< |
|
Definition
|
|
